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A B S T R A C T
Background
Intracranial venous thrombosis (ICVT) commonly presents with seizures in the acute period, and some people may develop recurrent
seizures in the long term. The prophylactic use of antiepileptic drugs (AEDs) for themanagement of post-ICVT seizures is controversial,
and there is currently no consensus on the optimal management of post-ICVT seizures. This is an updated version of the original
Cochrane review published in The Cochrane Library 2006, Issue 3.
Objectives
To assess the effects of AEDs for the primary and secondary prevention of seizures related to ICVT.
(1) For the question of primary prevention, we aimed to examine whether AEDs reduce the likelihood of seizures in people who have
had an ICVT but have not had a seizure.
(2) For the question of secondary prevention, we aimed to examine whether AEDs reduce the likelihood of further seizures in people
who have had an ICVT and at least one seizure.
Search methods
We aimed to identify relevant studies in the Cochrane Epilepsy Group and Cochrane Stroke Group Specialised Registers. We also
undertook specialised searches of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2013, Issue
7) and MEDLINE (Ovid 1946 to 22 August 2013) and checked the reference lists of articles retrieved from the searches.
Selection criteria
We considered all randomised and quasi-randomised controlled trials in which participants were assigned to a treatment group (that
is, receiving at least one AED) or control group (receiving placebo or no drug).
Data collection and analysis
Both review authors independently screened and assessed the methodological quality of the studies. If studies had been included in the
review, then one review author would have extracted the data and the other would have checked the extracted data.
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Main results
No relevant studies were found.
Authors’ conclusions
There is no evidence to support or refute the use of antiepileptic drugs for the primary or secondary prevention of seizures related
to intracranial venous thrombosis. Well-designed randomised controlled trials are urgently needed to inform practice. Since the last
version of this review no new studies have been found.
P L A I N L A N G U A G E S U M M A R Y
Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis (ICVT)
Review question
We reviewed the evidence around the use of antiepileptic medication to prevent seizures after intracranial venous thrombosis.
Background
Intracranial venous thrombosis is caused by blood clots in a vein or venous sinus in the brain. This can result in seizure activity. It
remains unclear which people with intracranial venous thrombosis should receive antiepileptics as a preventative treatment. We wanted
to clarify the potential benefit balanced with the potential side effects from using antiepileptic medication in this group of people.
Study characteristics
No study up to August 2013 met the inclusion criteria for review.
Key results
There is currently no evidence from randomised controlled trials to support or refute the use of antiepileptic drugs for the prevention
of seizures related to intracranial venous thrombosis.
B A C K G R O U N D
Description of the condition
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews (Issue 3, 2006) on
’Antiepileptic drugs for the primary and secondary prevention of
seizures after intracranial venous thrombosis’.
Intracranial venous thrombosis (ICVT) is the obstruction of one
or more of the cerebral veins or venous sinuses, which causes a
rise of venous pressure in its drainage territory (that is, venous
hypertension) leading to venous engorgement and brain oedema
(Arquizan 2002). This can lead to reducedbloodflow in the region.
The affected cerebral cortex and underlying white matter may
become congested, swollen and haemorrhagic, leading to venous
infarction (Arquizan 2002).
ICVT was first described by Ribes in 1825. At that time the con-
dition was largely regarded as fatal, with the majority of diag-
noses beingmade at post-mortem (Benamer 2000).More recently,
the diagnosis of ICVT has become easier to confirm with new
and less invasive neuroimaging techniques such as magnetic reso-
nance imaging (MRI) (Connor 2002). This has resulted in early
treatment and thus much better prognosis than was previously
thought possible. In the recent International Study on Cerebral
Vein and Dural Sinus Thrombosis, the 30-day case fatality rate
was only 3.4%, and the median time from onset to death was 13
days (Canhao 2005a). Another prospective study found that at
six months after ICVT 16% of participants had died, 7% were
dependent for daily activities, and 77% were independent (Stolz
2005). Treatments of ICVT with anticoagulation, thrombolysis,
and corticosteroids have been subjects of several recent Cochrane
reviews (Canhao 2002; Ciccone 2004; Stam 2004).
The exact frequency of ICVT in the general population is unclear
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(Arquizan 2002). Nevertheless, it is relatively rare and accounts
for less than 1% of all strokes (Masuhr 2004). ICVT can occur in
all age groups, with the highest incidence being amongst neonates
and adults in their third decade. ICVT is more common amongst
females (female/male ratio of 1.5 to 5). Due to the wide spec-
trum of clinical symptoms and gradual onset of symptoms, the
diagnosis is often missed or delayed. Important causes and predis-
posing factors include intracranial or systemic infections, coagu-
lation disorders (for example protein C or S deficiency), vascular
trauma (for example neurosurgery, head injury), space-occupying
lesions (for example intracranial and extracranial malignancies),
hormonal factors (for example the oral contraceptive pill, preg-
nancy, puerperium), vasculitis (for example lupus erythematosus,
Behçet’s disease), metabolic disorders (for example homocystin-
uria, hyperhomocysteinaemia), and others (for example following
a lumbar puncture). However, in up to a third of people there may
be no identifiable cause (Allroggen 2000; Canhao 2005b; Heller
2003; Masuhr 2004).
There are several key pathophysiological differences between ar-
terial and venous thrombosis in the brain. Firstly, ICVT is widely
regarded as a continuing process in which the balance of pro-
thrombotic and thrombolytic processes is disturbed, leading to
progression of the venous thrombus with time. This slow growth
of the thrombus, together with good collateralisation of venous
vessels, could explain why some people present with more gradual
onset of symptoms, often over days or weeks. In one retrospec-
tive multicentre study of 48 participants 44% presented acutely,
35% presented subacutely, and 21% presented in a chronic state
(Terazzi 2005). Secondly, haemorrhagic transformation occurs in
a significant proportion of people, probably as a result of raised
venous and capillary pressure at and around the site of occlusion
(Allroggen 2000).
The clinical presentation of ICVT depends on the extent and
site of venous occlusion, the progression of the thrombotic pro-
cess, and the existence of venous collaterals (Masuhr 2004; Van
den Bergh 2005). Occlusion of a large venous sinus may lead to
more generalised neurological sequelae, such as intracranial hy-
pertension, epileptic seizures, and altered consciousness, with a
poorer outcome. Involvement of isolated cortical veinsmay present
with more focal neurological symptoms such as motor or sensory
deficits and focal seizures (Van den Bergh 2005). In some mild
cases headache might be the only presenting feature (Cumurciuc
2005).
Description of the intervention
Compared with people with strokes caused by arterial occlusion,
those with ICVT are much more likely to experience seizures
at the initial presentation and during follow-up (Buccino 2003;
De Bruijn 2001; Ferro 2003; Masuhr 2004). In one series of
59 participants with ICVT 47% experienced seizures on admis-
sion (De Bruijn 2001). In another series of 142 participants with
ICVT 34% experienced seizures within the first two weeks of
the event, and 10% experienced seizures after the first two weeks
(Ferro 2003). In another series of 77 participants 36% experienced
seizures in the acute period (undefined) but only 5% developed
recurrent seizures (Preter 1996). The frequency of seizures may be
even higher amongst childrenwith ICVT. In a series of 58 children
with ICVT 58% experienced seizures on admission, and those
presenting with seizures were more likely to have a bad outcome
(DeVeber 2001). In Ferro 2003, early seizures were found to be
more frequent in people with motor and sensory deficits and in
those with computed tomography (CT) or MRI evidence of focal
brain oedema, venous infarction, or intracerebral haemorrhage on
admission. Furthermore, late seizures were more frequent in peo-
ple with early seizures and CT or MRI evidence of haemorrhage.
However, the relationship between post-ICVT seizures and out-
come remains unclear; some studies have identified seizures as a
poor prognostic indicator (Benamer 2000; DeVeber 2001; Stolz
2005) whilst others have not found such a relationship (Ferro
2003).
How the intervention might work
The prophylactic use of antiepileptic drugs (AEDs) for the man-
agement of post-ICVT seizures is controversial. In Ferro 2003,
of the 31 participants who experienced early seizures after ICVT
18 (58%) were prescribed AEDs, and of the 60 participants who
did not experience early seizures 12 (20%) were prescribed AEDs.
There is currently no consensus on the optimal management of
post-ICVT seizures. Whilst some experts recommend prophylac-
tic treatment with AEDs for all people with ICVT because of the
high risk of seizures and their potential adverse physiological ef-
fects (Einhaupl 1994), others have more recently recommended
reserving prophylactic treatment only for those who have already
had a seizure, that is, for secondary preventiononly (Buccino 2003;
Masuhr 2004). On the other hand, Ferro 2003 was specific in rec-
ommending that prophylactic treatment should be used in those
with proven risk factors for seizures (for example those who have
already experienced seizures or who have CT or MRI evidence of
haemorrhage).
Why it is important to do this review
This is an update of a previously published review in the Cochrane
Database of Systematic Reviews first published in 2006 and pre-
viously updated in 2011, which previously found no evidence to
support or refute the use of AEDs for the primary or secondary
prevention of seizures related to ICVT.
Overall, it remains unclearwhich peoplewith ICVTshould receive
prophylactic AEDs andwhich drug should be used, atwhat dosage,
and for how long (Masuhr 2004). Any potential benefits of using
AEDs should also be balanced with their potential side effects.
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This systematic review aimed to review updated evidence to assess
the potential benefits and risks of AEDs for the prevention of
seizures related to ICVT.
O B J E C T I V E S
To assess the effects of AEDs for the primary and secondary pre-
vention of seizures related to ICVT.
(1) For the question of primary prevention, we aimed to examine
whether AEDs reduce the likelihood of seizures in people who
have had an ICVT but have not had a seizure.
(2) For the question of secondary prevention, we aimed to examine
whether AEDs reduce the likelihood of further seizures in people
who have had an ICVT and at least one seizure.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised and quasi-randomised controlled
trials in which participants were assigned to a treatment group
(that is, receiving at least one AED) or control group (that is,
receiving placebo or no drug).
Types of participants
We considered all studies that had recruited participants with a
diagnosis of ICVT (including cerebral venous thrombosis and du-
ral sinus thrombosis), regardless of aetiology or method of diag-
nosis, and who had, or had not, experienced seizures post-ICVT.
For studies which reported the results for a mixture of participant
groups (for example arterial and venous thromboses) we attempted
to separate them and identify those results which were relevant to
the participant groups of interest. If this was not possible, despite
contacting the investigators, the studies were subjected to a sensi-
tivity analysis to determine the effects of including and excluding
the studies. Children or adults with generalised or focal seizures,
or both, were included.
Types of interventions
AEDswere any of those listed in the Cochrane Epilepsy Group in-
formation page, including carbamazepine, clobazam, clonazepam,
diazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam,
lorazepam, oxcarbazepine, phenytoin, phenobarbitone, primi-
done, sodium valproate, tiagabine, topiramate, vigabatrin, and
zonisamide. We considered all trials in which the intervention was
compared with a placebo or with no drug.
Types of outcome measures
Primary outcome measures
The primary outcome was the proportion of participants who ex-
perienced clinical seizures in the scheduled follow-up period. In
cases where seizures had occurred, their nature (generalised or fo-
cal), timing (early or late), and whether an electroencephalography
had been performed were noted. The investigators were contacted
if the outcome data were not readily available in the published
report. As described in the Background, seizures occurring within
the first week of ICVT were defined as early seizures, and those
occurring after the first week were defined as late seizures (ILAE
1981). Occurrence of recurrent late seizures was defined as post-
ICVT epilepsy.
Secondary outcome measures
(1) Proportion of participants who achieved remission for a pre-
defined period of time (for example 12 or 24 months).
(2) Proportion of participants who suffered status epilepticus.
(3) Proportion of participants who withdrew from the allocated
treatment within the scheduled follow-up period. This was a com-
posite outcome which takes into account several factors includ-
ing adverse events, compliance, and effectiveness of treatment.We
were particularly interested in the occurrence of side effects for
the different AEDs, which may be physical or neurobehavioural
(for example problems with memory, attention, and performance
skills).
(4) Proportion of participants who were dead or dependent at the
end of the scheduled follow-up period. ’Independent’ individuals
were to be defined as those who did not require regular physical
assistance from another person for activities of daily living, such as
mobility, dressing, transfers, and feeding. ’Dependent’ individuals
were to be those who failed to meet one or more of these criteria.
Other outcomes of interest
(1) Quality of life (for example using recognised scoring system
such as SF36 and EuroQol).
(2) Duration of hospital stay for the acute phase of recovery after
ICVT.
(3) ’Optimal’ duration of treatment (that is, length of time that
the intervention should be continued).
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Search methods for identification of studies
This search was run for the original review in October 2005, and
subsequent searches have been run in January 2010, August 2011,
and August 2013. For the latest update the following databases
were searched:
1. Cochrane Epilepsy Group Specialised Register on 27
August 2013, using the search strategy outlined in Appendix 1.
2. Cochrane Sroke Group Specialised Register on 12 August
2013, using the search strategy outlined in Appendix 2.
3. Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library 2013, Issue 7), using the
search strategy outlined in Appendix 3.
4. MEDLINE (Ovid 1946 to 22 August 2013). The
MEDLINE search strategy is outlined in Appendix 4.
We also checked the reference lists of articles retrieved from the
above searches.Where clarification of information was needed, we
attempted to contact the investigators of the relevant studies.
Data collection and analysis
Selection of trials
Both review authors screened all the titles, abstracts, and keywords
of publications identified by the searches to assess their eligibility.
Publications that clearly did not meet the inclusion criteria were
excluded at this stage. We obtained a paper copy of the full publi-
cation of every study that might possibly be relevant. Both review
authors assessed each one according to pre-specified selection cri-
teria. Any disagreement was resolved by discussion.
Assessment of methodological quality
If studies had been included, both review authors would have in-
dependently assessed the methodological quality of the included
studies and recorded the findings. We would have noted the im-
portant aspects of methodology: study design, type of control,
methodof allocation concealment, completeness of follow-up, and
the presence of blinding for assessments of non-fatal outcomes.
Data extraction
If studies had been included, one review author (JK) would have
extracted the data onto a data extraction form and the other re-
view author (AG)would have independently checked the extracted
data.Data reported by the published sources would have been used
for the analyses in this review. Where additional outcome data had
been needed, wewould have attempted to contact the investigators
of the studies. Apart from the methodology and outcome data,
we also planned to extract demographic data (for example total
number of participants randomised, number of participants per
group, age and sex distribution) and possible confounding factors.
These could have included certainty of diagnosis of ICVT, loca-
tion and aetiology of venous thrombosis, severity of condition,
presence of a venous infarct, previous history of epilepsy, other
co-morbid disorders, method and duration of treatments such as
anticoagulation, number of participants who withdrew from the
study or were lost during follow-up, and duration of follow-up.
Any disagreement would have been resolved by discussion and a
consensus decision made.
Data analysis
If studies had been included, data analysis would have abided by
the guidelines set out by The Cochrane Collaboration regarding
statistical methods. Primary analysis would have been by inten-
tion-to-treat. For dichotomous data, we planned to express rela-
tive treatment effects as odds or risk ratios, as appropriate, with
95% confidence intervals. For continuous data, we planned to use
weighted mean differences with 95% confidence intervals. A P
value of less than 0.05 would have been taken as statistically sig-
nificant. Clinical heterogeneity would have been assessed by the
distribution of demographic and prognostic variables across the
treatment and control groups. Statistical heterogeneity between
studies would have been assessed using the I2 statistic and the Q
test for heterogeneity. Where there was no significant clinical or
statistical heterogeneity, and if it appeared sensible to combine the
results, we planned to undertake a meta-analysis using a random-
effects model.
R E S U L T S
Description of studies
Results of the search
No study met the inclusion criteria that were set out in this re-
view. For this update, literature searches identified four articles.
For the 2011 update, 17 articles were identified. None of the arti-
cles identified were of studies that assessed the effects of AEDs for
the primary or secondary prevention of seizures related to ICVT.
Hence, no data were available for extraction or analysis.
Included studies
No studies met the inclusion criteria.
Excluded studies
All studies identifiedwere excluded as they did notmeet the criteria
for review.
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Risk of bias in included studies
No relevant studies were found.
Effects of interventions
No data from relevant studies were available for analysis.
D I S C U S S I O N
Summary of main results
We did not find any studies that assessed the effects of AEDs for
the primary or secondary prevention of seizures related to ICVT.
Despite the relatively low incidence of ICVT, the clinical problem
of post-ICVT seizures is still an important one. Previous observa-
tional studies have reported a high frequency of seizures follow-
ing ICVT as well as a possible correlation with poor functional
outcome. There is currently no consensus on the optimal strategy
to prevent post-ICVT seizures, and this systematic review has not
found any evidence to support or refute the use of AEDs for this
purpose. The balance between the relative benefits and risks of
treatment with AEDs remains unclear.
Overall completeness and applicability of
evidence
We did not find any studies that assessed the effects of AEDs for
the primary or secondary prevention of seizures related to ICVT.
Quality of the evidence
Well-designed randomised controlled trials are needed to provide
the necessary high-level evidence to effectively informclinical prac-
tice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence to support or refute the use of antiepileptic
drugs for the primary or secondary prevention of seizures related
to intracranial venous thrombosis .
Implications for research
No study has been conducted to evaluate the safety and effects
of antiepileptic drugs for the primary or secondary prevention of
seizures related to intracranial venous thrombosis. Well-designed
randomised controlled trials are, therefore, urgently needed to in-
form clinical practice. Such clinical trials should consider includ-
ing the following clinically relevant outcomes as outlined in this
systematic review.
• Proportion of participants who experience seizures (and
status epilepticus) in the scheduled follow-up period.
• Proportion of participants who achieve remission for a pre-
defined period of time.
• Proportion of participants who withdraw from the allocated
treatment in the scheduled follow-up period, and the reasons for
withdrawal.
• Proportion of participants who are dead or dependent at
the end of the scheduled follow-up period.
• Quality of life.
• Duration of hospital stay.
• Optimal duration of treatment.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Cochrane Epilepsy Group Specialised Register search strategy
#1 MeSH DESCRIPTOR Anticonvulsants Explode All WITH AD AE AG AN AI BL CF CS CH CL CT DU EC HI IM IP ME PK
PD PO RE ST SD TU TO UR
#2 anticonvulsant* OR antiepilep* OR phenytoin OR valpro* OR carbamazepine OR ethosuximide OR phenobarbit* OR primidone
#3 MeSH DESCRIPTOR Phenobarbital Explode All WITH AD AE AG AA AN AI BL CF CS CH CL CT DU EC HI IM IP ME
PK PD PO RE ST SD TU TO UR
#4 clobazam or clonazepam or diazepam or gabapentin or lamotrigine or levetiracetam or lorazapam or oxcarbazepine OR tiagabine
or topiramate or vigabatrin or zonisamide
#5 #1 OR #2 OR #3 OR #4
#6 MeSH DESCRIPTOR Intracranial Embolism and Thrombosis Explode All WITH BL CF CI CL CO CN DI DH DT EC EM
EN EP EH ET GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#7 MeSH DESCRIPTOR Intracranial Thrombosis Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET
GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#8 MeSH DESCRIPTOR Sinus Thrombosis, Intracranial Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP
EH ET GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#9 MeSH DESCRIPTOR Intracranial Embolism Explode All WITH BL CF CI CL CO CN DI DHDT EC EM EN EP EH ET GE
HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#10 MeSH DESCRIPTOR Cerebral Veins Explode All WITH AB AH CH CY DE EM EN GD IM IN IR MEMI PS PA PH PP RE
RA RI SE SU TR US UL VI
#11 MeSH DESCRIPTOR Cavernous Sinus Explode All WITH AB AH CH CY DE EM EN GD IM IN IR ME MI PS PA PH PP
RE RA RI SE SU US UL VI
#12 MeSH DESCRIPTOR Cranial Sinuses Explode All WITH AB AH CH CY DE EM EN GD IM IN IR ME MI PS PA PH PP
RE RA RI SE SU US UL VI
#13 MeSH DESCRIPTOR Dura Mater Explode All WITH AB AH BS CH CY DE EM EN GD IM IN ME MI PS PA PH PP RE
RA RI SE SU TR US UL VI
#14 #10 OR #11 OR #12 OR #13
#15 MeSH DESCRIPTOR Venous Thrombosis Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE
HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#16 MeSH DESCRIPTOR Thrombosis Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE HI IM
ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#17 MeSH DESCRIPTOR Thromboembolism Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE
HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#18 #15 OR #16 OR #17
#19 #14 AND #18
#20 (sinus* or sinovenous or cerebral venous or cerebral vein*) NEAR5 thrombo*
#21 (cavernous or sagittal venous or sagittal vein* or sinus) NEAR5 thrombo*
#22 cvdst or dct
#23 #6 OR #7 OR #8 OR #9 OR #19 OR #20 OR #21 OR #22
#24 #5 AND #23
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Appendix 2. Cochrane Stroke Group Specialised Register search strategy
Search method: 1
Stage: Not specified
Disease: Not specified
Condition: Seizures
Intervention type: Pharmacology
Intervention code: Not specified
Appendix 3. CENTRAL search strategy
#1 (epilep* or seizure* or convulsion*):ti,ab,kw
#2 (anticonvulsant* or antiepilep*):ti,ab,kw
#3 MeSH descriptor Epilepsy explode all trees
#4 MeSH descriptor Seizures explode all trees
#5 MeSH descriptor Anticonvulsants explode all trees
#6 (phenytoin or valpro* or carbamazepine):ti,ab,kw
#7 (ethosuximide OR phenobarbit* or primidone):ti,ab,kw
#8 MeSH descriptor Phenobarbital explode all trees
#9 (clobazam OR clonazepam or diazepam):ti,ab,kw
#10 (gabapentin or lamotrigine or levetiracetam):ti,ab,kw
#11 (lorazapam OR oxcarbazepine OR tiagabine):ti,ab,kw
#12 (topiramate OR vigabatrin OR zonisamide):ti,ab,kw
#13 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14 MeSH descriptor Intracranial Embolism and Thrombosis explode all trees
#15 MeSH descriptor Intracranial Thrombosis explode all trees
#16 MeSH descriptor Sinus Thrombosis, Intracranial explode all trees
#17 MeSH descriptor Intracranial Embolism explode all trees
#18 MeSH descriptor Cerebral Veins explode all trees
#19 MeSH descriptor Cavernous Sinus explode all trees
#20 MeSH descriptor Cranial Sinuses explode all trees
#21 MeSH descriptor Dura Mater explode all trees
#22 (#18 OR #19 OR #20 OR #21)
#23 MeSH descriptor Venous Thrombosis explode all trees
#24 MeSH descriptor Thrombosis explode all trees
#25 MeSH descriptor Thromboembolism explode all trees
#26 (#23 OR #24 OR #25)
#27 (#22 AND #26)
#28 (sinus* or sinovenous or cerebral venous or cerebral vein*) NEAR/5 thrombo*
#29 (cavernous or sagittal venous or sagittal vein* or sinus) NEAR/5 thrombo*
#30 (cvdst OR dct)
#31 (#14 OR #15 OR #16 OR #17 OR #27 OR #28 OR #29 OR #30)
#32 (#13 AND #31)
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Appendix 4. MEDLINE search strategy
The following search strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (Lefebvre
2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Epilepsy/
12. exp Seizures/
13. (epilep$ or seizure$ or convuls$).tw.
14. anticonvulsant$.tw.
15. exp ANTICONVULSANTS/
16. antiepilep$.tw.
17. phenytoin.tw.
18. valpro$.tw.
19. carbamazepine.tw.
20. ethosuximide.tw.
21. phenobarbit$.tw.
22. exp PHENOBARBITAL/
23. primidone.tw.
24. or/11-23
25. “Intracranial Embolism and Thrombosis”/
26. Intracranial Thrombosis/
27. exp Sinus Thrombosis, Intracranial/
28. Intracranial Embolism/
29. Cerebral Veins/
30. Cavernous Sinus/
31. Cranial Sinuses/
32. exp Dura Mater/
33. 29 or 30 or 31 or 32
34. Venous Thrombosis/
35. THROMBOSIS/
36. THROMBOEMBOLISM/
37. 34 or 35 or 36
38. 33 and 37
39. ((sinus$ or sinovenous or cerebral venous or cerebral vein$ or cavernous or sagittal venous or sagittal vein$ or sinus) adj5
thrombo$).tw.
40. (cvdst or cvt).tw.
41. 25 or 26 or 27 or 28 or 38 or 39 or 40
42. 10 and 24 and 41
Earlier versions of this review used the following search strategy. We received guidance from the Cochrane Stroke Group for the stroke
section (lines 39 to 54) of the search strategy for MEDLINE. The epilepsy and intervention sections of the search strategy (lines 22 to
36) were standard for the Cochrane Epilepsy Group. Lines 1 to 21 are drawn from the Cochrane highly sensitive search strategy for
identifying randomised trials in MEDLINE as set out in Appendix 5b of the Cochrane Handbook for Systematic Reviews of Interventions
(version 4.2.4, updated March 2005) (Higgins 2005).
1. randomized controlled trial.pt.
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2. controlled clinical trial.pt.
3. exp Randomized Controlled Trials/
4. exp Random Allocation/
5. exp Double-Blind Method/
6. exp Single-Blind Method/
7. 1 or 2 or 3 or 4 or 5 or 6
8. (animals not humans).sh.
9. 7 not 8
10. clinical trial.pt.
11. Clinical Trial/
12. (clin$ adj trial$).ab,ti.
13. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ab,ti.
14. exp PLACEBOS/
15. placebo$.ab,ti.
16. random$.ab,ti.
17. exp Research Design/
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. (animals not humans).sh.
20. 18 not 19
21. 9 or 20
22. epilep$.tw.
23. exp EPILEPSY/
24. seizure$.tw. [
25. exp SEIZURES/
26. convulsion$.tw.
27. anticonvulsant$.tw.
28. exp ANTICONVULSANTS/
29. antiepilep$.tw.
30. phenytoin.tw.
31. valpro$.tw.
32. carbamazepine.tw.
33. ethosuximide.tw.
34. phenobarbit$.tw. [
35. exp PHENOBARBITAL/
36. primidone.tw.]
37. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. 21 and 37
39. “Intracranial Embolism and Thrombosis”/
40. Intracranial Thrombosis/
41. exp Sinus Thrombosis, Intracranial/
42. Intracranial Embolism/
43. Cerebral Veins/
44. Cavernous Sinus/
45. Cranial Sinuses/
46. exp Dura Mater/
47. 43 or 44 or 45 or 46
48. Venous Thrombosis/
49. THROMBOSIS/
50. THROMBOEMBOLISM/
51. 48 or 49 or 50
52. 47 and 51
53. ((sinus$ or sinovenous or cerebral venous or cerebral vein$ or cavernous or sagittal venous or sagittal vein$ or sinus) adj5
thrombo$).tw.
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54. (cvdst or cvt).tw.
55. 39 or 40 or 41 or 42 or 52 or 53 or 54
56. 38 and 55
WH A T ’ S N E W
Last assessed as up-to-date: 12 August 2013.
Date Event Description
12 August 2013 New search has been performed Searches updated 12th August 2013; no new trials iden-
tified.
12 August 2013 New citation required but conclusions have not changed Conclusions remain the same.
H I S T O R Y
Protocol first published: Issue 4, 2005
Review first published: Issue 3, 2006
Date Event Description
31 August 2011 New search has been performed Searches updated 31st August 2011; no new trials identified.
17 March 2010 Amended Co-author’s contact details updated.
6 January 2010 New search has been performed Searches updated 6th January 2010; no new trials identified.
16 September 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Dr Joseph Kwan and Dr Albrecht Guenther screened the studies and wrote the original text of the review. Dr Michelle Price screened
the studies and added any updated text for this review.
13Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D E C L A R A T I O N S O F I N T E R E S T
None.
S O U R C E S O F S U P P O R T
Internal sources
• University of Southampton, UK.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [∗therapeutic use]; Intracranial Thrombosis [∗complications]; Seizures [etiology; ∗prevention & control]; Venous
Thrombosis [∗complications]
MeSH check words
Humans
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